# A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

> **NCT07736638** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 64 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ABBV-859
- **DRUG:** Placebo for ABBV-859
- **DRUG:** ABBV-859
- **DRUG:** Placebo for ABBV-859

## Key facts

- **NCT ID:** NCT07736638
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-28
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736638, "A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07736638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*